CN111212646A - 用于治疗弥漫性大b细胞淋巴瘤的组合物和方法 - Google Patents

用于治疗弥漫性大b细胞淋巴瘤的组合物和方法 Download PDF

Info

Publication number
CN111212646A
CN111212646A CN201880066675.2A CN201880066675A CN111212646A CN 111212646 A CN111212646 A CN 111212646A CN 201880066675 A CN201880066675 A CN 201880066675A CN 111212646 A CN111212646 A CN 111212646A
Authority
CN
China
Prior art keywords
blinatumomab
variant
pembrolizumab
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880066675.2A
Other languages
English (en)
Chinese (zh)
Inventor
扎卡里·齐默尔曼
晓红·阿莉西亚·张
彼得·克里斯托弗·霍兰
珍妮特·富兰克林
格雷戈里·弗里贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck&co Ltd
Amgen Inc
Original Assignee
Mercer East Pharmaceutical Factory
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercer East Pharmaceutical Factory, Amgen Inc filed Critical Mercer East Pharmaceutical Factory
Publication of CN111212646A publication Critical patent/CN111212646A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880066675.2A 2017-10-13 2018-10-12 用于治疗弥漫性大b细胞淋巴瘤的组合物和方法 Pending CN111212646A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13
US62/571,870 2017-10-13
PCT/US2018/055667 WO2019075366A1 (en) 2017-10-13 2018-10-12 COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS

Publications (1)

Publication Number Publication Date
CN111212646A true CN111212646A (zh) 2020-05-29

Family

ID=64110107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066675.2A Pending CN111212646A (zh) 2017-10-13 2018-10-12 用于治疗弥漫性大b细胞淋巴瘤的组合物和方法

Country Status (15)

Country Link
US (1) US20200262919A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694520A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020536923A (cg-RX-API-DMAC7.html)
KR (1) KR20200068655A (cg-RX-API-DMAC7.html)
CN (1) CN111212646A (cg-RX-API-DMAC7.html)
AU (1) AU2018347457A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3075291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090565A1 (cg-RX-API-DMAC7.html)
IL (1) IL273805A (cg-RX-API-DMAC7.html)
MX (2) MX2020003395A (cg-RX-API-DMAC7.html)
SG (1) SG11202002374RA (cg-RX-API-DMAC7.html)
TW (1) TW201922283A (cg-RX-API-DMAC7.html)
WO (1) WO2019075366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
TW202200615A (zh) * 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
WO2024097218A1 (en) * 2022-11-01 2024-05-10 TeneoTwo, Inc. Methods of treating non-hodgkin lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020065A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität Subcutaneously administered bispecific antibodies for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020065A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität Subcutaneously administered bispecific antibodies for use in the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREAS VIARDOT等: "Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma", 《BLOOD》 *
LUIS MIGUEL JUÁREZ-SALCEDO等: "The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now", 《CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY》 *
PIER LUIGI ZINZANI等: "Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma", 《BLOOD》 *

Also Published As

Publication number Publication date
CA3075291A1 (en) 2019-04-18
JP2024001071A (ja) 2024-01-09
KR20200068655A (ko) 2020-06-15
MX2024001888A (es) 2024-02-29
TW201922283A (zh) 2019-06-16
BR112020007203A2 (pt) 2020-10-20
EP3694520A1 (en) 2020-08-19
MX2020003395A (es) 2020-08-03
JP2020536923A (ja) 2020-12-17
SG11202002374RA (en) 2020-04-29
EA202090565A1 (ru) 2020-10-13
WO2019075366A1 (en) 2019-04-18
CL2020000973A1 (es) 2020-12-28
AU2018347457A1 (en) 2020-04-09
US20200262919A1 (en) 2020-08-20
IL273805A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
RU2766890C2 (ru) Комбинированные способы лечения антагонистами pd-l1
JP6586087B2 (ja) Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療
US20190270812A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
JP6783312B2 (ja) がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ
RU2737216C2 (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
WO2015119923A1 (en) Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
EP3856251B1 (en) Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
CN110678750A (zh) 用于癌症治疗的生物标志物
JP2024001071A (ja) びまん性大細胞型b細胞リンパ腫を治療するための組成物及び方法
CN110072552A (zh) 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合
US20210347889A1 (en) Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
RU2846266C2 (ru) Способы лечения злокачественного новообразования с использованием антител против pd-1
HK1228930A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK1232153B (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240507

Address after: U.S.A.

Applicant after: Merck&Co., Ltd.

Country or region after: U.S.A.

Applicant after: AMGEN Inc.

Address before: new jersey

Applicant before: Mercer East Pharmaceutical Factory

Country or region before: U.S.A.

Applicant before: AMGEN Inc.

TA01 Transfer of patent application right